Antidepressant effectiveness of deep Transcranial Magnetic Stimulation (dTMS) in patients with Major Depressive Disorder (MDD) with or without Alcohol Use Disorders (AUDs): A 6-month, open label, follow-up study
Chiara Rapinesi, Martina Curto, Georgios D. Kotzalidiscorrespondenceemail, Antonio Del Casale, Daniele Serata, Vittoria Rachele Ferri, Simone Di Pietro, Paola Scatena, Francesco Saverio Bersani, Ruggero Nessim Raccah, Vittorio Digiacomantonio, Stefano Ferracuti, Giuseppe Bersani, Abraham Zangen, Gloria Angeletti, Paolo Girardi. Published Online: November 20, 2014. Journal of affected disorders.
This study was designed to evaluate the effects of Brainsway® Deep TMS (Transcranial Magnetic Stimulation) in depression patients, with (n=11) or without (n=12) concomitant Alcohol Use Disorders (AUD). In the study, following 20 Deep TMS treatments, there was a substantial improvement of symptoms across groups, with faster improvement in patients who suffered from both depression and AUD. Significantly, these beneficial effects of the treatment were still visible at the 6-month follow-up. The study showed that Deep TMS is well tolerated and effective in depression patients, both with and without alcohol use disorder.
Brainsway's international website includes clinical and regulatory data for indications which were not cleared by the FDA for use in the United States.
This site is not intended for residents of the United States, its territories, and Puerto Rico.
The FDA cleared Brainsway's Deep TMS system for use in the U.S for treatment of depressive episodes in adult patients suffering from Major Depressive Disorder who failed to achieve satisfactory improvement from previous anti-depressant medication treatment in the current episode.
Would you like to proceed to the international website? To proceed click here
or click here to close this window